MARKET

FSTX

FSTX

F-star Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.81
+0.15
+2.25%
Closed 19:51 05/11 EDT
OPEN
6.46
PREV CLOSE
6.66
HIGH
7.08
LOW
6.35
VOLUME
162.02K
TURNOVER
--
52 WEEK HIGH
15.50
52 WEEK LOW
3.880
MARKET CAP
61.97M
P/E (TTM)
-0.7030
1D
5D
1M
3M
1Y
5Y
Stocks That Hit 52-Week Lows On Monday
  Monday morning saw 78 companies set new 52-week lows.
Benzinga · 1d ago
F-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patien...
Globe Newswire · 1d ago
70 Biggest Movers From Friday
Gainers InnSuites Hospitality Trust (NYSE: IHT) shares gained 43.4% to close at $3.50 on Friday.
Benzinga · 1d ago
Mid-Afternoon Market Update: Dow Surges Over 200 Points; ChemoCentryx Shares Drop
Toward the end of trading Friday, the Dow traded up 0.62% to 34,761.24 while the NASDAQ rose 0.95% to 13,762.12. The S&P also rose, gaining 0.74% to 4,232.81.
Benzinga · 4d ago
Why F-star Therapeutics' Stock Is Trading Lower Today
F-star Therapeutics (NASDAQ:FSTX) shares are trading lower after the company priced its 9.29 million shares common stock offering at $7 per share.
Benzinga · 4d ago
AUPH, MGI, EPZM and FROG among midday movers
Gainers: InnSuites Hospitality Trust (IHT) +95%.Regional Health Properties (RHE) +30%.Cooper-Standard (CPS) +25%.MoneyGram International (MGI) +23%.Epizyme (EPZM) +21%.The L.S. Starrett (SCX) +21%.Clene (CLNN) +20%.Yield10 Bioscience (YTEN) +20%.Phio Pharm...
Seekingalpha · 4d ago
Regional Health Properties, Auris Medical leads healthcare gainers; ChemoCentryx, Orphazyme among major losers
Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aurinia Pharmaceuticals (AUPH) ...
Seekingalpha · 4d ago
DJ F-star Therapeutics Prices Public Offering of 9.3M Shares at $7/Shr
Dow Jones · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FSTX. Analyze the recent business situations of F-star Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FSTX stock price target is 26.00 with a high estimate of 35.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 59
Institutional Holdings: 5.24M
% Owned: 57.53%
Shares Outstanding: 9.10M
TypeInstitutionsShares
Increased
3
342.90K
New
5
684.34K
Decreased
11
290.68K
Sold Out
7
42.05K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
  • All
  • Financials
  • Insiders
More
About FSTX
F-Star Therapeutics, Inc., formerly Spring Bank Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus (HBV). The Company's inarigivir selectively activates within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company also developing a second STING (STimulator of INterferon Genes) agonist product candidate, SB 11285, which is an immunotherapeutic agent for the potential treatment of selected cancers. The Company lead product is inarigivir.

Webull offers kinds of F-Star Therapeutics Inc stock information, including NASDAQ:FSTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FSTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FSTX stock methods without spending real money on the virtual paper trading platform.